Browse CCND1

Summary
SymbolCCND1
Namecyclin D1
Aliases U21B31; parathyroid adenomatosis 1; B-cell CLL/lymphoma 1; G1/S-specific cyclin D1; BCL1; D11S287E; PRAD1; c ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Membrane Note=Cyclin D-CDK4 complexes accumulate at the nuclear membrane and are then translocated to the nucleus through interaction with KIP/CIP family members.
Domain PF02984 Cyclin
PF00134 Cyclin
Function

Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner.

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0000082 G1/S transition of mitotic cell cycle
GO:0000086 G2/M transition of mitotic cell cycle
GO:0000320 re-entry into mitotic cell cycle
GO:0001889 liver development
GO:0006986 response to unfolded protein
GO:0007050 cell cycle arrest
GO:0007093 mitotic cell cycle checkpoint
GO:0007346 regulation of mitotic cell cycle
GO:0007548 sex differentiation
GO:0007584 response to nutrient
GO:0007589 body fluid secretion
GO:0007595 lactation
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0009314 response to radiation
GO:0009411 response to UV
GO:0009416 response to light stimulus
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010039 response to iron ion
GO:0010165 response to X-ray
GO:0010212 response to ionizing radiation
GO:0010389 regulation of G2/M transition of mitotic cell cycle
GO:0010948 negative regulation of cell cycle process
GO:0010971 positive regulation of G2/M transition of mitotic cell cycle
GO:0016055 Wnt signaling pathway
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030856 regulation of epithelial cell differentiation
GO:0030857 negative regulation of epithelial cell differentiation
GO:0030879 mammary gland development
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031570 DNA integrity checkpoint
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0031667 response to nutrient levels
GO:0031960 response to corticosteroid
GO:0032026 response to magnesium ion
GO:0032355 response to estradiol
GO:0032941 secretion by tissue
GO:0033197 response to vitamin E
GO:0033273 response to vitamin
GO:0033327 Leydig cell differentiation
GO:0033598 mammary gland epithelial cell proliferation
GO:0033599 regulation of mammary gland epithelial cell proliferation
GO:0033601 positive regulation of mammary gland epithelial cell proliferation
GO:0033674 positive regulation of kinase activity
GO:0034620 cellular response to unfolded protein
GO:0034976 response to endoplasmic reticulum stress
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0042493 response to drug
GO:0043627 response to estrogen
GO:0044321 response to leptin
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044783 G1 DNA damage checkpoint
GO:0044819 mitotic G1/S transition checkpoint
GO:0044839 cell cycle G2/M phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045137 development of primary sexual characteristics
GO:0045444 fat cell differentiation
GO:0045471 response to ethanol
GO:0045737 positive regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045860 positive regulation of protein kinase activity
GO:0045930 negative regulation of mitotic cell cycle
GO:0045931 positive regulation of mitotic cell cycle
GO:0046546 development of primary male sexual characteristics
GO:0046661 male sex differentiation
GO:0048545 response to steroid hormone
GO:0048608 reproductive structure development
GO:0048732 gland development
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050878 regulation of body fluid levels
GO:0051384 response to glucocorticoid
GO:0051385 response to mineralocorticoid
GO:0051412 response to corticosterone
GO:0051592 response to calcium ion
GO:0060070 canonical Wnt signaling pathway
GO:0060749 mammary gland alveolus development
GO:0061008 hepaticobiliary system development
GO:0061180 mammary gland epithelium development
GO:0061377 mammary gland lobule development
GO:0061458 reproductive system development
GO:0070141 response to UV-A
GO:0071156 regulation of cell cycle arrest
GO:0071157 negative regulation of cell cycle arrest
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0090068 positive regulation of cell cycle process
GO:0097305 response to alcohol
GO:0097421 liver regeneration
GO:0198738 cell-cell signaling by wnt
GO:1901654 response to ketone
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901989 positive regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1901992 positive regulation of mitotic cell cycle phase transition
GO:1902749 regulation of cell cycle G2/M phase transition
GO:1902751 positive regulation of cell cycle G2/M phase transition
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1904029 regulation of cyclin-dependent protein kinase activity
GO:1904031 positive regulation of cyclin-dependent protein kinase activity
GO:1990267 response to transition metal nanoparticle
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
Molecular Function GO:0003714 transcription corepressor activity
GO:0008134 transcription factor binding
GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity
GO:0019207 kinase regulator activity
GO:0019887 protein kinase regulator activity
GO:0042826 histone deacetylase binding
GO:0070064 proline-rich region binding
Cellular Component GO:0000307 cyclin-dependent protein kinase holoenzyme complex
GO:0005923 bicellular tight junction
GO:0017053 transcriptional repressor complex
GO:0043296 apical junction complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0070160 occluding junction
GO:1902554 serine/threonine protein kinase complex
GO:1902911 protein kinase complex
> KEGG and Reactome Pathway
 
KEGG hsa04068 FoxO signaling pathway
hsa04110 Cell cycle
hsa04115 p53 signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04310 Wnt signaling pathway
hsa04340 Hedgehog signaling pathway
hsa04390 Hippo signaling pathway
hsa04510 Focal adhesion
hsa04530 Tight junction
hsa04630 Jak-STAT signaling pathway
hsa04917 Prolactin signaling pathway
hsa04919 Thyroid hormone signaling pathway
hsa04921 Oxytocin signaling pathway
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-69656: Cyclin A
R-HSA-69231: Cyclin D associated events in G1
R-HSA-69202: Cyclin E associated events during G1/S transition
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-69236: G1 Phase
R-HSA-69206: G1/S Transition
R-HSA-168256: Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-8849470: PTK6 Regulates Cell Cycle
R-HSA-1912422: Pre-NOTCH Expression and Processing
R-HSA-1912408: Pre-NOTCH Transcription and Translation
R-HSA-3214858: RMTs methylate histone arginines
R-HSA-69242: S Phase
R-HSA-187577: SCF(Skp2)-mediated degradation of p27/p21
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-157118: Signaling by NOTCH
R-HSA-8848021: Signaling by PTK6
R-HSA-75815: Ubiquitin-dependent degradation of Cyclin D
R-HSA-69229: Ubiquitin-dependent degradation of Cyclin D1
Summary
SymbolCCND1
Namecyclin D1
Aliases U21B31; parathyroid adenomatosis 1; B-cell CLL/lymphoma 1; G1/S-specific cyclin D1; BCL1; D11S287E; PRAD1; c ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCND1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CCND1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
19225534Mantle cell lymphomaPromote immunity; immnuotherapy targetThese results indicate that these T cells are potent cytotoxic T cells and recognize cyclin D1 peptides naturally presented by patient lymphoma cells in the context of HLA-A(*)0201 molecules. Taken together, our work identifies cyclin D1 as a potentially important antigen for immunotherapy of MCL.
Summary
SymbolCCND1
Namecyclin D1
Aliases U21B31; parathyroid adenomatosis 1; B-cell CLL/lymphoma 1; G1/S-specific cyclin D1; BCL1; D11S287E; PRAD1; c ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCND1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCCND1
Namecyclin D1
Aliases U21B31; parathyroid adenomatosis 1; B-cell CLL/lymphoma 1; G1/S-specific cyclin D1; BCL1; D11S287E; PRAD1; c ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCND1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2610.536
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0230.731
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.30.895
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2150.625
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.140.953
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3160.912
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4240.439
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2670.904
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.1840.628
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1250.955
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5260.867
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6320.00502
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CCND1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCCND1
Namecyclin D1
Aliases U21B31; parathyroid adenomatosis 1; B-cell CLL/lymphoma 1; G1/S-specific cyclin D1; BCL1; D11S287E; PRAD1; c ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCND1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCND1
Namecyclin D1
Aliases U21B31; parathyroid adenomatosis 1; B-cell CLL/lymphoma 1; G1/S-specific cyclin D1; BCL1; D11S287E; PRAD1; c ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCND1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCND1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCND1
Namecyclin D1
Aliases U21B31; parathyroid adenomatosis 1; B-cell CLL/lymphoma 1; G1/S-specific cyclin D1; BCL1; D11S287E; PRAD1; c ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCND1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCND1
Namecyclin D1
Aliases U21B31; parathyroid adenomatosis 1; B-cell CLL/lymphoma 1; G1/S-specific cyclin D1; BCL1; D11S287E; PRAD1; c ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCND1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCND1
Namecyclin D1
Aliases U21B31; parathyroid adenomatosis 1; B-cell CLL/lymphoma 1; G1/S-specific cyclin D1; BCL1; D11S287E; PRAD1; c ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCND1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCND1
Namecyclin D1
Aliases U21B31; parathyroid adenomatosis 1; B-cell CLL/lymphoma 1; G1/S-specific cyclin D1; BCL1; D11S287E; PRAD1; c ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCND1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CCND1.
ID Name Drug Type Targets #Targets
DB01169Arsenic trioxideSmall MoleculeAKT1, CCND1, CDKN1A, HDAC1, IKBKB, JUN, MAPK1, MAPK3, PML, TXNRD110